Galapagos NV (GLPG.AS)
EUR 25.7
(0.78%)
EUR 25.7
(0.78%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 51.03 Million EUR | 117.92% |
| 2022 | -33.36 Million EUR | -40.64% |
| 2021 | -100.92 Million EUR | 16.58% |
| 2020 | -294.51 Million EUR | -142.41% |
| 2019 | 374.24 Million EUR | 1212.3% |
| 2018 | -28.86 Million EUR | 57.7% |
| 2017 | -109.81 Million EUR | -1354.25% |
| 2016 | -8.16 Million EUR | 89.71% |
| 2015 | -115.99 Million EUR | -88.99% |
| 2014 | -30.33 Million EUR | -1499.51% |
| 2013 | -7.7 Million EUR | -121.52% |
| 2012 | 4.01 Million EUR | 142.64% |
| 2011 | -21.49 Million EUR | -240.49% |
| 2010 | 13.78 Million EUR | 47.71% |
| 2009 | 8.83 Million EUR | 436.41% |
| 2008 | -1.88 Million EUR | 50.5% |
| 2007 | -12.4 Million EUR | 5.06% |
| 2006 | -6.71 Million EUR | -29.96% |
| 2005 | -4.88 Million EUR | -95.01% |
| 2004 | -2.34 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | -48.44 Million EUR | -1074.96% |
| 2024 Q2 | -14.88 Million EUR | 118.2% |
| 2024 Q1 | -7.42 Million EUR | 58.01% |
| 2023 Q2 | 7.08 Million EUR | -79.96% |
| 2023 FY | - EUR | 117.92% |
| 2023 Q1 | 35.32 Million EUR | 131.57% |
| 2023 Q4 | -45.02 Million EUR | -621.44% |
| 2023 Q3 | -6.24 Million EUR | -188.15% |
| 2022 Q3 | -26.43 Million EUR | 37.76% |
| 2022 Q1 | -17.07 Million EUR | -245.75% |
| 2022 Q2 | -42.47 Million EUR | -148.7% |
| 2022 Q4 | -111.89 Million EUR | -323.27% |
| 2022 FY | - EUR | -40.64% |
| 2021 Q4 | 11.71 Million EUR | 116.66% |
| 2021 FY | - EUR | 16.58% |
| 2021 Q1 | -47.74 Million EUR | -102.38% |
| 2021 Q2 | -31.63 Million EUR | 33.76% |
| 2021 Q3 | -70.34 Million EUR | -122.38% |
| 2020 Q4 | -23.59 Million EUR | 42.68% |
| 2020 FY | - EUR | -142.41% |
| 2020 Q3 | -41.15 Million EUR | 49.06% |
| 2020 Q2 | -80.8 Million EUR | -306.71% |
| 2020 Q1 | -19.86 Million EUR | 87.11% |
| 2019 Q2 | -42.94 Million EUR | 14.94% |
| 2019 FY | - EUR | 1212.3% |
| 2019 Q4 | -154.1 Million EUR | -124.22% |
| 2019 Q1 | -50.48 Million EUR | -299.15% |
| 2019 Q3 | 636.16 Million EUR | 1581.38% |
| 2018 FY | - EUR | 57.7% |
| 2018 Q2 | -31.26 Million EUR | -1.37% |
| 2018 Q3 | 13.4 Million EUR | 142.87% |
| 2018 Q1 | -30.84 Million EUR | 39.46% |
| 2018 Q4 | 25.35 Million EUR | 89.14% |
| 2017 Q3 | -28.58 Million EUR | -38.88% |
| 2017 FY | - EUR | -1354.25% |
| 2017 Q2 | -20.58 Million EUR | -102.26% |
| 2017 Q1 | -10.17 Million EUR | -110.47% |
| 2017 Q4 | -50.94 Million EUR | -78.23% |
| 2016 Q4 | 97.18 Million EUR | 521.51% |
| 2016 Q2 | -5.91 Million EUR | 91.99% |
| 2016 FY | - EUR | 89.71% |
| 2016 Q1 | -73.91 Million EUR | -206.2% |
| 2016 Q3 | -23.05 Million EUR | -289.66% |
| 2015 Q4 | -24.13 Million EUR | 10.45% |
| 2015 Q1 | -14.62 Million EUR | -76.8% |
| 2015 FY | - EUR | -88.99% |
| 2015 Q3 | -26.95 Million EUR | -40.71% |
| 2015 Q2 | -19.15 Million EUR | -31.01% |
| 2014 Q1 | -6.17 Million EUR | -75.84% |
| 2014 FY | - EUR | -1499.51% |
| 2014 Q4 | -8.27 Million EUR | 13.91% |
| 2014 Q3 | -9.6 Million EUR | -55.57% |
| 2014 Q2 | -6.17 Million EUR | 0.0% |
| 2013 Q3 | -3.51 Million EUR | -241.97% |
| 2013 Q4 | -3.51 Million EUR | 0.0% |
| 2013 Q2 | -1.02 Million EUR | 0.0% |
| 2013 Q1 | -1.02 Million EUR | -127.97% |
| 2013 FY | - EUR | -121.52% |
| 2012 Q2 | - EUR | 0.0% |
| 2012 Q4 | -450.5 Thousand EUR | -108.24% |
| 2012 FY | - EUR | 142.64% |
| 2012 Q3 | 5.47 Million EUR | 0.0% |
| 2011 Q4 | - EUR | 0.0% |
| 2011 Q2 | - EUR | 0.0% |
| 2011 FY | - EUR | -240.49% |
| 2010 Q4 | - EUR | 0.0% |
| 2010 FY | - EUR | 47.71% |
| 2010 Q2 | - EUR | 0.0% |
| 2009 Q2 | - EUR | 0.0% |
| 2009 Q4 | - EUR | 0.0% |
| 2009 FY | - EUR | 436.41% |
| 2008 FY | - EUR | 50.5% |
| 2008 Q4 | - EUR | 0.0% |
| 2007 FY | - EUR | 5.06% |
| 2006 FY | - EUR | -29.96% |
| 2005 FY | - EUR | -95.01% |
| 2004 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.29 Million EUR | 1651.277% |
| ABIVAX Société Anonyme | -133.2 Million EUR | 138.314% |
| Adocia SA | -22.73 Million EUR | 324.516% |
| Aelis Farma SA | -6.34 Million EUR | 904.112% |
| Biophytis S.A. | -13.8 Million EUR | 469.726% |
| Advicenne S.A. | -6.24 Million EUR | 917.377% |
| genOway Société anonyme | 6.35 Million EUR | -703.637% |
| IntegraGen SA | -52.5 Thousand EUR | 97307.779% |
| Medesis Pharma S.A. | -3.84 Million EUR | 1427.4% |
| Neovacs S.A. | -8.44 Million EUR | 704.021% |
| NFL Biosciences SA | -4.04 Million EUR | 1360.39% |
| Plant Advanced Technologies SA | 72.53 Thousand EUR | -70266.745% |
| Quantum Genomics Société Anonyme | -2.87 Million EUR | 1876.139% |
| Sensorion SA | -22.31 Million EUR | 328.724% |
| Theranexus Société Anonyme | -7.38 Million EUR | 790.881% |
| TME Pharma N.V. | -5.07 Million EUR | 1106.25% |
| Valbiotis SA | -6.95 Million EUR | 833.817% |
| TheraVet SA | -517.33 Thousand EUR | 9965.349% |
| Valerio Therapeutics Société anonyme | -18.91 Million EUR | 369.809% |
| argenx SE | -199.5 Million EUR | 125.582% |
| BioSenic S.A. | -6.79 Million EUR | 850.986% |
| Celyad Oncology SA | -7.76 Million EUR | 757.439% |
| DBV Technologies S.A. | -79.53 Million EUR | 164.173% |
| Genfit S.A. | -28.05 Million EUR | 281.944% |
| GeNeuro SA | -14.31 Million EUR | 456.461% |
| Hyloris Pharmaceuticals SA | -14.98 Million EUR | 440.701% |
| Innate Pharma S.A. | -7.57 Million EUR | 773.489% |
| Inventiva S.A. | -101.84 Million EUR | 150.111% |
| MaaT Pharma SA | -19.74 Million EUR | 358.546% |
| MedinCell S.A. | -20.04 Million EUR | 354.599% |
| Nanobiotix S.A. | -34.01 Million EUR | 250.025% |
| Onward Medical N.V. | -35.23 Million EUR | 244.852% |
| Oryzon Genomics S.A. | -4.43 Million EUR | 1251.204% |
| OSE Immunotherapeutics SA | -23.26 Million EUR | 319.363% |
| Oxurion NV | -16.72 Million EUR | 405.081% |
| Pharming Group N.V. | 4.98 Million EUR | -924.641% |
| Poxel S.A. | -12.17 Million EUR | 519.057% |
| GenSight Biologics S.A. | -21.73 Million EUR | 334.869% |
| Transgene SA | -27.02 Million EUR | 288.858% |
| Financière de Tubize SA | 184.57 Thousand EUR | -27551.69% |
| UCB SA | 1.26 Billion EUR | 95.978% |
| Valneva SE | -64.51 Million EUR | 179.106% |
| Vivoryon Therapeutics N.V. | -28.35 Million EUR | 280.006% |